Phase I/II Study of High-Dose Calcitriol Plus Temodar for Patients With Metastatic Melanoma
| Status: | Completed |
|---|---|
| Conditions: | Skin Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 12/30/2018 |
| Start Date: | January 30, 2005 |
| End Date: | December 7, 2012 |
A Phase I/II Study of High-Dose Calcitriol in Combination With Temozolomide for Patients With Metastatic Melanoma
RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop
the growth of tumor cells, either by killing the cells or by stopping them from dividing.
Calcitriol may help temozolomide kill more tumor cells by making them more sensitive to the
drug. Calcitriol may also stop the growth of melanoma by blocking blood flow to the tumor.
PURPOSE: This phase I/II trial is studying the best dose of calcitriol, the side effects of
calcitriol when given together with temozolomide, and to see how well they work in treating
patients with metastatic stage IV melanoma.
the growth of tumor cells, either by killing the cells or by stopping them from dividing.
Calcitriol may help temozolomide kill more tumor cells by making them more sensitive to the
drug. Calcitriol may also stop the growth of melanoma by blocking blood flow to the tumor.
PURPOSE: This phase I/II trial is studying the best dose of calcitriol, the side effects of
calcitriol when given together with temozolomide, and to see how well they work in treating
patients with metastatic stage IV melanoma.
* Phase I: Patients receive oral calcitriol on days 1 and 15 and oral temozolomide on days
2-8 and 16-22. Treatment repeats every 28 days for 2 courses in the absence of unacceptable
toxicity. Responding patients continue therapy for up to 6 courses in the absence of
unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of calcitriol until the maximum tolerated
dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6
patients experience dose limiting toxicity.
- Phase II: Patients receive temozolomide and calcitriol at the MTD as in phase I.
After completion of study treatment, patients are followed every 3 months.
2-8 and 16-22. Treatment repeats every 28 days for 2 courses in the absence of unacceptable
toxicity. Responding patients continue therapy for up to 6 courses in the absence of
unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of calcitriol until the maximum tolerated
dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6
patients experience dose limiting toxicity.
- Phase II: Patients receive temozolomide and calcitriol at the MTD as in phase I.
After completion of study treatment, patients are followed every 3 months.
Inclusion Criteria:
- Histologically confirmed malignant melanoma
- Any primary tumor site
- Stage IV disease
- CNS metastases allowed
- Measurable disease, defined as at least 1 lesion that can be accurately measured in at
least 1 dimension as ≥ 20 mm by conventional techniques OR ≥ 10 mm by spiral CT scan
- Must have had at least 1 prior systemic therapy
- Negative pregnancy test
- Fertile patients must use effective contraception
- Patients with no prior systemic therapy are eligible provided they are not
candidates for high-dose interleukin-2
- Recovered from all toxic effects of prior therapy
- More than 4 weeks since prior and no concurrent radiotherapy, chemotherapy, or
immunotherapy
- More than 4 weeks since prior and no concurrent radiotherapy, chemotherapy, or
immunotherapy
- Fertile patients must use effective contraception
Exclusion Criteria:
- Life expectancy less than 4 months
- known HIV positivity
- evidence of active infection requiring antibiotic therapy
- other malignancy within the past 5 years except surgically resected basal cell or
squamous cell skin cancer
- significant medical disease which, in the opinion of the investigator, may interfere
with study completion
- pregnant or nursing
- Negative pregnancy test
- prior temozolomide or dacarbazine
- investigational agent within 4 weeks prior to study entry
- concurrent magnesium-containing antacids, digitalis, bile-resin binding drugs, or
calcium supplements
We found this trial at
1
site
675 N Saint Clair St # 21-100
Chicago, Illinois 60611
Chicago, Illinois 60611
(312) 695-1156
Robert H. Lurie Comprehensive Cancer Center at Northwestern University The cancer center was first established...
Click here to add this to my saved trials
